Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2025 09:15 ET | Source: Nutriband Inc.

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

Dividend dates reminder
July 02, 2025 08:05 ET | Source: Nutriband Inc.

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

Stock dividend
July 01, 2025 07:00 ET | Source: Nutriband Inc.

Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

NTRB Added to 4 Russell Indexes
June 18, 2025 07:00 ET | Source: Nutriband Inc.

Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Commercial Scale up complete for AVERSA
June 09, 2025 07:30 ET | Source: Nutriband Inc.

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

New Patent issuance
June 03, 2025 08:00 ET | Source: Nutriband Inc.

Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

noble conference announcement
June 02, 2025 08:00 ET | Source: Nutriband Inc.

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Q1 results
April 30, 2025 07:30 ET | Source: Nutriband Inc.

Nutriband CEO Publishes Letter to Shareholders

2025 Letter to Shareholders
April 11, 2025 07:00 ET | Source: Nutriband Inc.

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

Nutriband increases Patent protection with the addition of Macao
April 04, 2025 17:41 ET | Source: Nutriband Inc.

UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an...

Next Page keyboard_arrow_right